Larimar Therapeutics, Inc. (LRMR) Stock Price, Financials & Summary

Price chart

Oct 7Oct 12Oct 15Oct 20Oct 23Oct 28Nov 2Nov 5

Key dataNov 5, 2026

Open$2.75

From 52W high−61.01%

Volume1.76M

Market cap$241.01M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 5, 2026

Open

$2.75

From 52W high

−61.01%

Volume

1.76M

Market cap

$241.01M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.5x

P/E (TTM)

—

RSI (14)

47.0

MomentumView details →

1D Return

−15.94%

YTD Return

−33.46%

SummaryUpdated Jun 1, 2026

Larimar Therapeutics, Inc. (NASDAQ:LRMR) is a clinical-stage biotechnology company founded in 2014 and based in Bala Cynwyd, Pennsylvania. The company specializes in developing innovative treatments for rare diseases using its proprietary cell penetrating peptide technology platform. Since going public in 2014, Larimar has focused its efforts on advancing novel therapeutic approaches for conditions that currently have limited or no treatment options, with its lead program targeting Friedreich's ataxia, a devastating genetic disorder.

Ask drillr about Larimar Therapeutics, Inc. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.5x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.9x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−135.50%

ROA (TTM)

−104.42%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

−27.56%

FCF YoY

−68.57%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−71.97%

EBITDA YoY

−64.58%

MomentumView details →

1D Return

−15.94%

YTD Return

−33.46%

1Y Return

−26.95%

RSI (14)

47.0

vs 50D SMA

−17.89%

vs 200D SMA

−33.19%

Capital & dividendView details →

Debt/Equity

0.04x

Current Ratio

4.70x

Quick Ratio

4.70x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.30

EPS Surprise

21.35%

Beats (12Q)

6/12

Next Q EPS Est

−$0.38

Avg Surprise (4Q)

−14.86%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−172.60M

Op. CF (TTM)

−155.92M

Next earningsMar 19, 2027 →

Latest newsMore news →

Larimar Therapeutics announced that three poster presentations on its nomlabofusp program will be presented at the International Congress for Ataxia Research 2026.8h ago

Larimar Therapeutics appointed John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to CEO Carole Ben-Maimon.37d ago

Similar companies

Shanghai Bio-heart Biological Technology Co., Ltd.02185.HK Lexeo Therapeutics, Inc. Common StockLXEO Amarin Corporation plcAMRN Bicycle Therapeutics plcBCYC I-MabIMAB CAMP4 Therapeutics CorporationCAMP Find similar companies →

Latest newsMore news →

Larimar Therapeutics announced that three poster presentations on its nomlabofusp program will be presented at the International Congress for Ataxia Research 2026.8h ago Larimar Therapeutics appointed John Harlow as President and Chief Operating Officer, effective September 29, 2026, reporting to CEO Carole Ben-Maimon.37d ago